Deep-vein thrombosis occurred in 2.51% of patients in the aspirin group and 1.71% in the low-molecular-weight–heparin group (difference, 0.80 percentage points; 95% CI, 0.28 to 1.31).

Unfractionated vs. low-molecular-weight heparin (LMWH): Find out what the difference is and how they work for DVT.

Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to ...

Discover the findings of the ALIFE2 trial on low-molecular-weight heparin (LMWH) use for recurrent pregnancy loss and inherited thrombophilia. The ALIFE2 trial challenges the routine prescription ...

Patients with cancer who had acute, symptomatic proximal deep-vein thrombosis, pulmonary embolism, or both were randomly assigned to receive low-molecular-weight heparin (dalteparin) at a dose of ...

Low-molecular weight heparin was shown to be as effective as inpatient IV unfractionated heparin management in mechanical heart valve patients requiring interruption of chronic anticoagulation for ...

If both drugs are administered as they were in the study, the cost of a six-day course of low-molecular-weight heparin is about $712, compared with $37 for a similar course of unfractionated ...

The consensus in the American College of Chest Physicians (ACCP) statement published in Chest in 1998 did not recommend routine use of low-molecular-weight (LMW) heparin for outpatient treatment ...

McMaster University. "Low molecular weight heparin use in cancer treatment." ScienceDaily. ScienceDaily, 15 February 2012. <www.sciencedaily.com / releases / 2012 / 02 / 120215185838.htm>.

June 29, 2004 -- Low-molecular-weight heparin can serve as a bridge during warfarin interruption, according to the results of a trial of consecutive patients published in the June 28 issue of the ...